A number of key proposals to improve the transparency and effectiveness of the pharmaceutical industry's relationships with the NHS have been made to the House of Commons Select Committee inquiry into the industry's influence by the Association of the British Pharmaceutical Industry (ABPI), it was announced today.
As well as the recommendations - which range from requiring organisations engaging in clinical trial work with the NHS to publish the results, to developing further guidelines on industry's relationships with patient groups - the ABPI document also responds to some of the issues raised at the inquiry.
The ABPI document was submitted to the committee in advance of the oral evidence session being held on Thursday, January 13, at which the ABPI will be represented by Vincent Lawton, President of the ABPI, and Dr Richard Barker, Director General.
The recommendations have been made against a background of ABPI support for and commitment to more openness across the whole of the healthcare system.
The ABPI's recommendations cover a number of areas, including:
The pharmaceutical industry is already extremely highly regulated and committed to the highest standards of ethical and business conduct. But we recognise that an issue of trust has arisen, and greater trust needs to be built on increased transparency," said Dr Barker.
We believe these recommendations are practicable and that they go a long way towards addressing this issue."
The ABPI document also examines several areas which were identified by witnesses to the inquiry, including:
For further information, please contact: ABPI Press Office 020 7747 1410